Literature DB >> 7600563

Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.

D M Mahvi1, J A Madsen, P L Witt, P M Sondel.   

Abstract

Interferons up-regulate the expression of human tumor-associated antigens in animal models and in vitro. The use of interferons may enhance the immunodetection and immunotherapy of tumors by monoclonal antibodies that detect tumor antigens. For this strategy to be effective, however, the interferon must have an effect at the site of the tumor. In this study, the induction by interferon alpha (IFN alpha) of two tumor surface antigens was evaluated in six patients with primary colorectal cancer. Patients were treated with IFN alpha and 48 h later underwent resection of the tumor. The interferon treatment induced expression of a tumor-associated glycoprotein (TAG-72) in two patients without antigen expression prior to interferon but had no effect on one TAG-72-negative tumor. IFN alpha did not induce expression of carcinoembryonic antigen (CEA) in the two patients whose tumors were CEA-negative prior to interferon. In all patients with heterogeneous expression of CEA and TAG-72 prior to IFN alpha treatment, preoperative interferon increased the percentage of cells positive for CEA in two patients and TAG-72 in one patient. This study supports the addition of interferon induction to immunotherapy regimens directed at the CEA and TAG-72 cell-surface antigens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7600563     DOI: 10.1007/BF01519631

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  Effects of recombinant human gamma-interferon on carcinoembryonic antigen expression of human colon cancer cells.

Authors:  X W Yan; J Y Wong; J M Esteban; J A Kuhn; B G Beatty; J D Beatty; J E Shively
Journal:  J Immunother (1991)       Date:  1992-02

2.  Gamma-interferon enhancement of carcinoembryonic antigen expression in human colon carcinoma xenografts.

Authors:  J A Kuhn; J Y Wong; B G Beatty; J M Esteban; L E Williams; J D Beatty
Journal:  J Immunother (1991)       Date:  1992-05

3.  Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma.

Authors:  F Guadagni; P L Witt; P F Robbins; J Schlom; J W Greiner
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

4.  Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.

Authors:  F Guadagni; J Schlom; W W Johnston; C A Szpak; D Goldstein; R Smalley; J F Simpson; E C Borden; S Pestka; J W Greiner
Journal:  J Natl Cancer Inst       Date:  1989-04-05       Impact factor: 13.506

5.  Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells.

Authors:  J W Greiner; F Guadagni; D Goldstein; R V Smalley; E C Borden; J F Simpson; A Molinolo; J Schlom
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

6.  Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages.

Authors:  P L Witt; G T Spear; D O Helgeson; M J Lindstrom; R V Smalley; E C Borden
Journal:  J Interferon Res       Date:  1990-08

7.  In vitro and in vivo regulation of tumor antigen expression by human recombinant interferons.

Authors:  F Guadagni; J Schlom; J W Greiner
Journal:  Int J Rad Appl Instrum B       Date:  1991

8.  Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.

Authors:  J W Greiner; F Guadagni; D Goldstein; E C Borden; R E Ritts; P Witt; A F LoBuglio; M N Saleh; J Schlom
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

9.  Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo.

Authors:  J W Greiner; F Guadagni; P Noguchi; S Pestka; D Colcher; P B Fisher; J Schlom
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

10.  Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.

Authors:  J W Greiner; C D Ullmann; C Nieroda; C F Qi; D Eggensperger; S Shimada; S M Steinberg; J Schlom
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

View more
  2 in total

1.  A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Authors:  Megan C Duggan; Caroline Jochems; Renee N Donahue; Jacob Richards; Volodymyr Karpa; Elizabeth Foust; Bonnie Paul; Taylor Brooks; Susheela Tridandapani; Thomas Olencki; Xueliang Pan; Gregory B Lesinski; Jeffrey Schlom; William E Carson Iii
Journal:  Cancer Immunol Immunother       Date:  2016-08-31       Impact factor: 6.968

2.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.